GANX - Gain Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

GANX is currently covered by 3 analysts with an average price target of $6.59. This is a potential upside of $4.65 (239.69%) from yesterday's end of day stock price of $1.94.

Gain Therapeutics's activity chart (see below) currently has 7 price targets and 27 ratings on display. The stock rating distribution of GANX is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 5% with an average time for these price targets to be met of 42.8 days.

Highest price target for GANX is $8, Lowest price target is $6, average price target is $7.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 27-Mar-2025. First documented stock forecast 11-Apr-2021.

Best performing analysts who are covering GANX - Gain Therapeutics:

Mayank Mamtani Keay Nakae Raghuram Selvaraju Thomas Shrader Hartaj Singh

Currently out of the existing stock ratings of GANX, 22 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$6

$4.06 (209.28%)

$6

1 months 13 days ago
(27-Mar-2025)

0/5 (0%)

$3.93 (189.86%)

Buy

$8

$6.06 (312.37%)

$8

1 months 24 days ago
(16-Mar-2025)

0/14 (0%)

$5.6 (233.33%)

Buy

$9

8 months 27 days ago
(13-Aug-2024)

0/4 (0%)

$5.61 (165.49%)

Buy

$10

$7.27 (266.30%)

$30

2 years 6 months ago
(11-Nov-2022)

0/2 (0%)

$6.79 (211.53%)

Buy

$5

$2.27 (83.15%)

$11

2 years 8 months 22 days ago
(19-Aug-2022)

1/4 (25%)

$1.34 (36.61%)

214

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GANX (Gain Therapeutics) average time for price targets to be met?

On average it took 42.8 days on average for the stock forecasts to be realized with a an average price target met ratio 5

Which analyst has the current highest performing score on GANX (Gain Therapeutics) with a proven track record?

MAYANK MAMTANI

Which analyst has the current lower performing score on GANX (Gain Therapeutics) with a proven track record?

HARTAJ SINGH

Which analyst has the most public recommendations on GANX (Gain Therapeutics)?

Mayank Mamtani works at B. RILEY and has 3 price targets and 2 ratings on GANX

Which analyst is the currently most bullish on GANX (Gain Therapeutics)?

Thomas Shrader with highest potential upside - $7.27

Which analyst is the currently most reserved on GANX (Gain Therapeutics)?

Hartaj Singh with lowest potential downside - -$0

Gain Therapeutics in the News

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?